• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Brexpiprazole Intermediate CAS:70500-72-0
Brexpiprazole CAS:913611-97-9
3-BROMOPHENANTHRENE
2-FLUORO-4-(TRIFLUOROMETHYL)BENZOPHENONE
3-BROMO-4-FLUOROBIPHENYL
9-TRIFLUOROACETYLANTHRACENE

Zydus Cadila gets final US FDA nod for Pindolol tabs

expressbpdAugust 23, 2017

Tag: FDA , Zydus Cadila , Pindolol tabs

Zydus Cadila has received final approval from the US health regulator to market Pindolol tablets, used for treatment of hypertension.

The company has received approval from the US Food and Drug Administration (US FDA) to market the drug in the strengths of 5 mg and 10 mg, Zydus Cadila said in a BSE filing.

Pindolol belongs to a class of beta-blockers and is used to treat hypertension. The company said it will manufacture the drug at the groups manufacturing facility at the Pharma SEZ in Ahmedabad.

Previous:DRL out-licenses DFD-06 to Encore Dermatology

Next:Indian patent office grants patent to Pfizer for Prevnar 13

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Zydus Cadila gets final US FDA nod for Pindolol tabs | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Nabumetone (FDA)

Nabumetone (FDA)
Meclozine HCL (FDA)

Meclozine HCL (FDA)
Mitomycin ( FDA)

Mitomycin ( FDA)
Dobutamine HCL (FDA)

Dobutamine HCL (FDA)
Etoposide( FDA)

Etoposide( FDA)
Vecuronium Bromide(FDA)

Vecuronium Bromide(FDA)
Ifosfamide (FDA)

Ifosfamide (FDA)
Bleomycin sulfate (FDA)

Bleomycin sulfate (FDA)
Hemisuccinate /Sodium (FDA/DMF)

Hemisuccinate /Sodium (FDA/DMF)
Simvastatin (FDA)

Simvastatin (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service